PR Newswire Clinical TrialsOriginal article
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
ConferencePADCEVVYLOYpembrolizumabPositive
AI Analysis
Summary
Astellas presented clinical data at ESMO 2026 demonstrating durable survival benefits for PADCEV (enfortumab vedotin) plus pembrolizumab in advanced bladder cancer and reinforcing the role of CLDN18.2 in gastric cancer treatment with VYLOY (zolbetuximab).
Outcome Details
Data presented at ESMO 2026 showing durable survival benefit for PADCEV plus pembrolizumab in advanced bladder cancer and VYLOY research reinforcing CLDN18.2 role in gastric cancer treatment
Importance:5/10
Sentiment:
0.60
oncologybladder cancergastric cancercombination therapyESMO 2026clinical data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 6, 2026 11:30 PM